meplazumab

Home
Ligands
meplazumab

GtoPdb Ligand ID: 11026

Synonyms: HP6H8 | Ketantin®

Comment: Meplazumab is a humanized IgG2 monoclonal antibody that targets CD147 (basigin). It is being developed by Jiangsu Pacific Meinuoke Bio Pharmaceutical.

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.

SARS-CoV-2 and COVID-19: SARS-CoV-2 may utilise CD147 as an additional entry receptor to infect host cells [2]. Meplazumab can block this interaction between CD147 and SARS-CoV-2 spike protein.

Bioactivity Comments
Meplazumab has been evaluated using an in vitro growth inhibition assay against a panel of culture-adapted P. falciparum strains and found to have potent asexual blood stage activity. The EC₅₀ values ranged from 1.81 to ~31.64 ng/mL (panel included Pf3D7, PfDd2, and PfNf54) [4].

Bioactivity Comments

Meplazumab has been evaluated using an in vitro growth inhibition assay against a panel of culture-adapted P. falciparum strains and found to have potent asexual blood stage activity. The EC₅₀ values ranged from 1.81 to ~31.64 ng/mL (panel included Pf3D7, PfDd2, and PfNf54) [4].

Selectivity at other protein targets

Key to terms and symbols

Click on species/strain names for details

Click column headers to sort

Target			Sp.	Type	Action	Value	Parameter	Concentration range (M)	Reference
basigin (Ok blood group)			Hs	Antibody	Binding	-	-	-
⤷